<DOC>
	<DOCNO>NCT03103438</DOCNO>
	<brief_summary>This open label , phase 1 , `` 3+3 '' dose escalate study tolerability , safety , pharmacokinetics , pharmacodynamics immunogenicity single subcutaneous injection novel monoclonal antibody interleukin-6 receptor - BCD-089 . The study enroll 19 healthy male volunteer .</brief_summary>
	<brief_title>First-in-human Study Evaluate Safety , Pharmacokinetics Pharmacodynamics Various Doses BCD-089 Healthy Subjects</brief_title>
	<detailed_description>IL-6 new potential therapeutic target play important role pathogenesis several autoimmune disorder include rheumatoid arthritis . BCD-089 novel fully human monoclonal antibody interleukin-6 receptor develop JCS BIOCAD ( Russia ) first step clinical evaluation . BCD-089-1 study first-in-human clinical trial intend evaluate tolerability , safety , pharmacokinetics , pharmacodynamics immunogenicity BCD-089 use single step-by-step escalate subcutaneous dose healthy male volunteer . During study expect determine diapason safety dose BCD-089 ( incl . MTD ) thereafter evaluate phase 2 study .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>sing informed consent male gender 1845 year age inclusively BMI between18.530.0 kg/sq.m . absence sings hepatic , renal , gastrointestinal , cardiovascular , endocrine , respiratory , immunologic , hematologic , dermatologic , neurologic abnormality screen or/and anamnesis parameter complete blood count , blood biochemistry , urinalysis exceed reference value , use Study site laboratory normal hemodynamic parameter : absence chronic infection ( HIV , syphilis , hepatitis ะ ะก , tuberculosis ) chronic inflammation absence infection within 4 week screen absence mental disorder condition , may affect ability participant follow Protocol absence alcohol drug addiction sign ( incl . history addiction ) . volunteer 's ability follow Protocol procedure consent volunteer sexual partner childbearing potential use adequate contraception screen period main study part ( 14 day randomization 70 day SC injection ) . This requirement applicable surgically sterilize volunteer . Adequate contraception include use one barrier method combination spermicide , intrauterine device / oral contraceptive sexual partner history use monoclonal antibody IL6 IL6R know severe allergy ( anaphylaxis multidrug intolerance ) know intolerance medicine contain monoclonal antibody ( murine , humanize , human ) excipients BCD089 major surgery within 30 day prior screen severe infection ( require hospitalization , parenteral use antimicrobial agent ) within 6 month prior date BCD089 injection systemic use antimicrobial within 2 month prior date BCD089 injection 4 episode respiratory tract infection within 6 month prior screen examination presence disorder may affect pharmacokinetics BCD089 history fever equal exceed 40 degree Celsius actual prior depression , suicidal tendency use medicine , vitamin , biologically active additive within 14 day prior screen examination use medicine affect hemodynamics hepatic function within 30 day prior screen examination simultaneous participation clinical trial , well former participation clinical trial within 2 month study initiation . previous participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>